Colorectal CancerPhase 3NCT00003594
Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
A Phase 3 study testing irinotecan, fluorouracil and leucovorin calcium in people with Colorectal Cancer, run by Alliance for Clinical Trials in Oncology at 466 sites in 4 countries.
Trial summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is most effective in treating advanced colorectal cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colorectal Cancer
- What is being tested?
- irinotecan, fluorouracil and leucovorin calcium
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,691 participants
- Where
- 466 sitesin 4 countries
- Study dates
- Oct 1998to Oct 2004
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma not curable by surgery or radiotherapy
- Histological or cytological requirement waived in patients who developed radiological or clinical evidence of metastatic cancer after a prior surgical resection unless:
- More than 5 years has elapsed since primary surgery OR
- Primary cancer was stage I or II
- Site of primary lesion must be or have been confirmed endoscopically, radiologically, or surgically to be or have been in the large bowel
- Measurable or evaluable disease
- No CNS metastases or carcinomatous meningitis
PATIENT CHARACTERISTICS:
Age:
- 18 and over
Performance status:
- ECOG 0-2
Life expectancy:
- At least 12 weeks
Hematopoietic:
- Absolute granulocyte count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Hemoglobin at least 9.0 g/dL (transfusion allowed)
Hepatic:
- Bilirubin no greater than 1.5 mg/dL
- AST no greater than 5 times upper limit of normal (ULN)
- Alkaline phosphatase no greater than 5 times ULN
Renal:
- Creatinine no greater than 1.5 times ULN
Cardiovascular:
- No uncontrolled hypertension
- No unstable angina
- No symptomatic congestive heart failure
- No myocardial infarction within the past 6 months
- No serious uncontrolled arrhythmia
- No New York Heart Association class III or IV cardiac disease
Pulmonary:
- No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
- No pleural effusion or ascites that cause respiratory compromise (grade 2 or worse dyspnea)
Other:
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No active or uncontrolled infection
- No symptomatic sensory peripheral neuropathy
- No known allergy to platinum compounds
- No history of gastrointestinal bleeding unless it is determined to be acceptable by the enrolling physician
- No other prior or concurrent malignancy within the past 3 years except nonmelanoma skin cancer, carcinoma in situ of the uterine cervix, or other resected malignant tumor with less than a 10% probability of tumor relapse within 3 years of diagnosis
- No medical or psychiatric conditions that would preclude study
- No colonic or small bowel disorders with uncontrolled symptoms of more than 3 loose stools per day
- Colostomy or ileostomy allowed at investigator's discretion
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Prior adjuvant immunotherapy for resected stage II-IV disease allowed if adjuvant therapy concluded at least 1 year before documentation of recurrent disease
- No concurrent sargramostim (GM-CSF)
Chemotherapy:
- No prior chemotherapy for advanced colorectal cancer
- No prior standard adjuvant chemotherapy for rectal cancer
- Prior adjuvant fluorouracil for resected stage II-IV disease allowed if adjuvant therapy concluded at least 1 year before documentation of recurrent disease
Radiotherapy:
- See Disease Characteristics
- At least 4 weeks since prior major radiotherapy (e.g., chest or bone palliative radiotherapy)
- No prior radiotherapy to more than 15% of bone marrow
- No prior standard adjuvant radiotherapy for rectal cancer
Surgery:
- See Disease Characteristics
- At least 4 weeks since prior major surgery (e.g., laparotomy) (2 weeks for minor surgery) and recovered
- Insertion of a vascular access device not considered major or minor surgery
Other:
- No other concurrent investigational agents
Trial locations and contacts
466 sites in 4 countries.
336 sites in 4 countries
United States300 sites
Bixby Medical Center
Adrian, Michigan, 49221
Akron City Hospital
Akron, Ohio, 44309
Veterans Affairs Medical Center - Albuquerque
Albuquerque, New Mexico, 87108-5138
MBCCOP - University of New Mexico HSC
Albuquerque, New Mexico, 87131
Alexandria Clinic
Alexandria, Minnesota, 56308
Alexandria Radiation Oncology
Alexandria, Minnesota, 56308
Lehigh Valley Hospital
Allentown, Pennsylvania, 18103
McFarland Clinic, P.C.
Ames, Iowa, 50010
William R. Bliss Cancer Center
Ames, Iowa, 50010
Veterans Affairs Medical Center - Ann Arbor
Ann Arbor, Michigan, 48105
Saint Joseph Mercy Hospital
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0752
Anne Arundel Medical Center
Annapolis, Maryland, 21401
Fox Valley Hematology and Oncology
Appleton, Wisconsin, 54911
Cancer Center of Kansas - Arkansas City
Arkansas City, Kansas, 67005
Memorial Medical Center
Ashland, Wisconsin, 54806
Emory University Hospital - Atlanta
Atlanta, Georgia, 30322
Grady Memorial Hospital
Atlanta, Georgia, 30335
CCOP - Atlanta Regional
Atlanta, Georgia, 30342-1701
Columbia Medical Center of Aurora North Campus
Aurora, Colorado, 80011
Muhlenberg Hospital Center
Bethlehem, Pennsylvania, 18017
Hematology Oncology Associates of the Quad Cities
Bettendorf, Iowa, 52722
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Veterans Affairs Medical Center - Biloxi
Biloxi, Mississippi, 39531-2410
Veterans Affairs Medical Center - Birmingham
Birmingham, Alabama, 35233-1996
Bismarck Cancer Center
Bismarck, North Dakota, 58501-4445
Medcenter One Health System
Bismarck, North Dakota, 58501
Mid Dakota Clinic, P.C.
Bismarck, North Dakota, 58501
St. Alexius Medical Center
Bismarck, North Dakota, 58502
BroMenn Lifecare Center
Bloomington, Illinois, 61701-3081
St. Joseph's Hospital Medical Center
Bloomington, Illinois, 61701
New England Medical Center Hospital
Boston, Massachusetts, 02111
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
Boston Medical Center
Boston, Massachusetts, 02118
Wood County Oncology Center
Bowling Green, Ohio, 43402
Brainerd Medical Center
Brainerd, Minnesota, 56401
St. Joseph's Medical Center
Brainerd, Minnesota, 56401
Bristol Hospital
Bristol, Connecticut, 06011-0977
Veterans Affairs Medical Center - Buffalo
Buffalo, New York, 14215
Vermont Cancer Center
Burlington, Vermont, 05401-3498
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Graham Hospital Association
Canton, Illinois, 61520
Mercy Ireland Cancer Center
Canton, Ohio, 44708
Aultman Cancer Center
Canton, Ohio, 44710
Marion Community Hospital
Carbondale, Pennsylvania, 18407
Saint Anthony Regional Hospital
Carroll, Iowa, 51401
Memorial Hospital
Carthage, Illinois, 62321
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Medical Center
Cedar Rapids, Iowa, 52403
St. Luke's Hospital
Cedar Rapids, Iowa, 52406
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Lineberger Comprehensive Cancer Center, UNC
Chapel Hill, North Carolina, 27599-7295
Center for Cancer And Hematologic Disease
Cherry Hill, New Jersey, 08046
Hematology-Oncology Associates of Illinois
Chicago, Illinois, 60611-2998
Robert H. Lurie Comprehensive Cancer Center, Northwestern University
Chicago, Illinois, 60611-3013
Hematology Oncology Associates of Illinois - Lake Shore Dr
Chicago, Illinois, 60611
Veterans Affairs Medical Center - Lakeside Chicago
Chicago, Illinois, 60611
Veterans Affairs Medical Center - Chicago (Westside Hospital)
Chicago, Illinois, 60612
Mercy Hospital and Medical Center
Chicago, Illinois, 60616
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
Veterans Affairs Medical Center - Cincinnati
Cincinnati, Ohio, 45220-2288
Barrett Cancer Center, The University Hospital
Cincinnati, Ohio, 45267-0502
Ireland Cancer Center
Cleveland, Ohio, 44106-5065
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
Penrose Cancer Center
Colorado Springs, Colorado, 80933
Veterans Affairs Medical Center - Columbia (Truman Memorial)
Columbia, Missouri, 65201
Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, 65203
CCOP - Columbus
Columbus, Ohio, 43206
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, 43210-1240
Mercy Hospital
Coon Rapids, Minnesota, 55433
Mary Imogene Bassett Hospital
Cooperstown, New York, 13326
Alegent Health Southwest Iowa Medical Center
Council Bluffs, Iowa, 51503
Geisinger Medical Center
Danville, Pennsylvania, 17822-2001
Veterans Affairs Medical Center - Dayton
Dayton, Ohio, 45428
Veterans Affairs Medical Center - Atlanta (Decatur)
Decatur, Georgia, 30033
CCOP - Central Illinois
Decatur, Illinois, 62526
University of Colorado Cancer Center
Denver, Colorado, 80010
CCOP - Colorado Cancer Research Program, Inc.
Denver, Colorado, 80209-5031
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian-St Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
HealthOne Rose Medical Center
Denver, Colorado, 80220
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220
Des Moines General Hospital
Des Moines, Iowa, 50309
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates
Des Moines, Iowa, 50314
Mercy Hospital Medical Center
Des Moines, Iowa, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, 50316-2392
Holy Family Medical Center
Des Plaines, Illinois, 60016
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Veterans Affairs Medical Center - Detroit
Detroit, Michigan, 48201-1932
Henry Ford Hospital
Detroit, Michigan, 48202
St. John Hospital and Medical Center
Detroit, Michigan, 48236
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Radiation Oncology Center
Dodge City, Kansas, 67801
Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, 19026
Cancer Center and Beckman Research Institute, City of Hope
Duarte, California, 91010-3000
DuBois Regional Medical Center
DuBois, Pennsylvania, 15801-0447
Duluth Clinic
Duluth, Minnesota, 55805
Miller-Dwan Medical Center
Duluth, Minnesota, 55805
St. Mary's/Duluth Clinic Health System
Duluth, Minnesota, 55805
Veterans Affairs Medical Center - Durham
Durham, North Carolina, 27705
Duke Comprehensive Cancer Center
Durham, North Carolina, 27710
Luther Hospital
Eau Claire, Wisconsin, 54703
Midelfort Clinic
Eau Claire, Wisconsin, 54703
Fairview-Southdale Hospital
Edina, Minnesota, 55435
St. Anthony's Memorial Hospital
Effingham, Illinois, 62401
Trinitas Hospital - Jersey Street Campus
Elizabeth, New Jersey, 07201
Northwest Oncology and Hematology, S.C.
Elk Grove Village, Illinois, 60007
Swedish Medical Center
Englewood, Colorado, 80110
Eureka Hospital
Eureka, Illinois, 61530
CCOP - Evanston
Evanston, Illinois, 60201
Therapy Associates Hematology/Oncology
Evansville, Indiana, 47715
CCOP - Merit Care Hospital
Fargo, North Dakota, 58122
Meritcare Roger Maris Cancer Center
Fargo, North Dakota, 58122
University of Connecticut Health Center
Farmington, Connecticut, 06360-7106
Fergus Falls Medical Group
Fergus Falls, Minnesota, 56537
Woman Wise Blanchard Valley Regional Health Center
Findlay, Ohio, 45840
Hunterdon Regional Cancer Center
Flemington, New Jersey, 08822
Genesee Regional Medical Center
Flint, Michigan, 48503
Rocky Mountain Cancer Centers - Northern Colorado
Fort Collins, Colorado, 80524-4038
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Poudre Valley Radiation Oncology
Fort Collins, Colorado, 80528
Dwight David Eisenhower Army Medical Center
Fort Gordon, Georgia, 30905-5650
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
Fremont Area Medical Center
Fremont, Nebraska, 68025-2387
Fremont Memorial Hospital
Fremont, Ohio, 43420
Mercy/Unity Hospitals
Fridley, Minnesota, 55432
University of Florida - Gainesville
Gainesville, Florida, 32610-0277
Galesburg Clinic
Galesburg, Illinois, 61401
InterCommunity Cancer Center of Western Illinois
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61402
University of Texas Medical Branch
Galveston, Texas, 77555-0209
Glenbrook Hospital
Glenview, Illinois, 60025
Altru Health Systems
Grand Forks, North Dakota, 58201
Altru Cancer Center
Grand Forks, North Dakota, 58206
CCOP - Grand Rapids Clinical Oncology Program
Grand Rapids, Michigan, 49503
St. Vincent Hospital
Green Bay, Wisconsin, 54307-3508
UPMC Horizon
Greenville, Pennsylvania, 16125
CCOP - Greenville
Greenville, South Carolina, 29615
Halstead Cancer Center of Kansas
Halstead, Kansas, 67056
Pinnacle Health Hospitals
Harrisburg, Pennsylvania, 17105-8700
St. Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Ingalls Memorial Hospital
Harvey, Illinois, 60426
Mason District Hospital
Havana, Illinois, 62644
Central Mesabi Medical Center
Hibbing, Minnesota, 55746
Duluth Clinic - Hibbing
Hibbing, Minnesota, 55746
Radiation Therapy Center
Hibbing, Minnesota, 55746
Hematology Oncology Associates of Illinois-Highland Park
Highland Park, Illinois, 60035
Veterans Affairs Medical Center - Hines (Hines Junior VA Hospital)
Hines, Illinois, 60141
Hinsdale Hematology Oncology Associates
Hinsdale, Illinois, 60521
Wayne Memorial Hospital
Honesdale, Pennsylvania, 18431-1498
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813
Hopedale Medical Complex Hospital
Hopedale, Illinois, 61747
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Holden Comprehensive Cancer Center at The University of Iowa
Iowa City, Iowa, 52242-1009
University of Mississippi Medical Center
Jackson, Mississippi, 39216-4505
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216
Baptist Regional Cancer Institute - Jacksonville
Jacksonville, Florida, 32207
University of Florida Health Science Center - Jacksonville
Jacksonville, Florida, 32209
Mayo Clinic
Jacksonville, Florida, 32224
Faulkner Hospital
Jamaica Plain, Massachusetts, 02130
Veterans Affairs Medical Center - Boston (Jamaica Plain)
Jamaica Plain, Massachusetts, 02130
UPCI @ UPMC Lee Hospital
Johnstown, Pennsylvania, 15901
Conemaugh Memorial Hospital
Johnstown, Pennsylvania, 15905
Silver Cross Hospital
Joliet, Illinois, 60432
Joliet Oncology/Hematology Associates, Ltd.
Joliet, Illinois, 60435
Saint Joseph Medical Center
Joliet, Illinois, 60435
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Borgess Medical Center
Kalamazoo, Michigan, 49048-1666
University of Kansas Medical Center
Kansas City, Kansas, 66160-7357
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, 64128
CCOP - Kansas City
Kansas City, Missouri, 64131
Keesler Medical Center - Keesler AFB
Keesler Air Force Base, Mississippi, 39534-2576
Office of Sharon Cole, M.D.
Kenton, Ohio, 43326
CCOP - Dayton
Kettering, Ohio, 45429
Kewanee Hospital
Kewanee, Illinois, 61443
Cancer Center of Kansas - Kingman
Kingman, Kansas, 67068
Armstrong County Memorial Hospital
Kittanning, Pennsylvania, 16201-8808
Franciscan Skemp Healthcare
La Crosse, Wisconsin, 54601-4796
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
University of California San Diego Cancer Center
La Jolla, California, 92093-0658
Oncology Institute of Greater Lafayette
Lafayette, Indiana, 47904
Deerpath Medical Associates
Lake Forest, Illinois, 60045
Lancaster General Hospital
Lancaster, Pennsylvania, 17604-3555
Saint Mary Regional Center
Langhorne, Pennsylvania, 19047
Sparrow Regional Cancer Center
Lansing, Michigan, 48909
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Latrobe Area Hospital
Latrobe, Pennsylvania, 15650
Norris Cotton Cancer Center
Lebanon, New Hampshire, 03756-0002
Central Pennsylvania Hematology and Medical Oncology Associates
Lemoyne, Pennsylvania, 17043
Veterans Affairs Medical Center - Lexington
Lexington, Kentucky, 40511-1093
Albert B. Chandler Medical Center, University of Kentucky
Lexington, Kentucky, 40536-0084
Liberal Cancer Center of Kansas
Liberal, Kansas, 67901
North Shore Oncology Hematology Associates
Libertyville, Illinois, 60048
St. Rita's Medical Center
Lima, Ohio, 45801
Lima Memorial Hospital
Lima, Ohio, 45804
Bryan LGH Medical Center
Lincoln, Nebraska, 68502-3780
Prairie View Clinic
Lincoln, Nebraska, 68506-5247
Bryan LGH Medical Center East
Lincoln, Nebraska, 68506
Office of Susan Hansen, M.D.
Lincoln, Nebraska, 68506
St. Elizabeth Regional Medical Center
Lincoln, Nebraska, 68510
Wedgewood Medical Center
Lincoln, Nebraska, 68510
Southeast Nebraska Hematology
Lincoln, Nebraska, 68516
Southeast Nebreska Hematology-Oncology Consultants, PC
Lincoln, Nebraska, 68516
Williamsburg Radiation Oncology Center
Lincoln, Nebraska, 68516
Meeker County Memorial Hospital
Litchfield, Minnesota, 55355
University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Veterans Affairs Medical Center - Little Rock (McClellan)
Little Rock, Arkansas, 72205
Veterans Affairs Medical Center - Long Beach
Long Beach, California, 90822
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90033-0804
Veterans Affairs Medical Center - West Los Angeles
Los Angeles, California, 90073
Jonsson Comprehensive Cancer Center, UCLA
Los Angeles, California, 90095-1781
McDonough District Hospital
Macomb, Illinois, 61455
Veterans Affairs Medical Center - Madison
Madison, Wisconsin, 53705
Dean Medical Center
Madison, Wisconsin, 53715
Meriter Hospital
Madison, Wisconsin, 53715
University of Wisconsin Comprehensive Cancer Center
Madison, Wisconsin, 53792-6164
Office of E. Michael Lodish
Madison Heights, Michigan, 48071-3457
CCOP - North Shore University Hospital
Manhasset, New York, 11030
Schneider Children's Hospital at North Shore
Manhasset, New York, 11030
St. John's Hospital
Maplewood, Minnesota, 55109
CCOP - Marshfield Medical Research and Education Foundation
Marshfield, Wisconsin, 54449
Veterans Affairs Outpatient Clinic - Martinez
Martinez, California, 94553
Mercy Cancer Center
Mason City, Iowa, 50401
North West Ohio Oncology Center
Maumee, Ohio, 43537
Saint Luke's Hospital
Maumee, Ohio, 43537
Loyola University Medical Center
Maywood, Illinois, 60153
Lawrence Memorial Hospital of Medford/Hallmark Health Systems
Medford, Massachusetts, 02155
Hematology/Oncology Associates of Illinois, LLC
Melrose Park, Illinois, 60160
University of Tennessee, Memphis Cancer Center
Memphis, Tennessee, 38103
Veterans Affairs Medical Center - Memphis
Memphis, Tennessee, 38104
Mendota Community Hospital
Mendota, Illinois, 61342
CCOP - Mount Sinai Medical Center
Miami Beach, Florida, 33140
South Jersey Regional Cancer Center
Millville, New Jersey, 08332
Aurora Sinai Samaritan Medical Center
Milwaukee, Wisconsin, 53201-0342
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Veterans Affairs Medical Center - Milwaukee (Zablocki)
Milwaukee, Wisconsin, 53295
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Virginia Piper Cancer Institute
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Veterans Affairs Medical Center - Minneapolis
Minneapolis, Minnesota, 55417
North Memorial Research Center
Minneapolis, Minnesota, 55442-2900
Fairview University Medical Center - Riverside Campus
Minneapolis, Minnesota, 55454-1395
University of Minnesota Cancer Center
Minneapolis, Minnesota, 55455
Community Memorial Hospital
Missouri Valley, Iowa, 51555-1199
MBCCOP - Gulf Coast
Mobile, Alabama, 36688
Trinity Medical Center
Moline, Illinois, 61265-1291
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Community Hospital of the Monterey Peninsula
Monterey, California, 93940
Morris Hospital
Morris, Illinois, 60450
Fox Chase Cancer Center at Virtua Memorial Hospital Burlington County
Mount Holly, New Jersey, 08060
New Britain General Hospital
New Britain, Connecticut, 06050
Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
Lawrence and Memorial Hospital
New London, Connecticut, 06320
MBCCOP - LSU Health Sciences Center
New Orleans, Louisiana, 70112
Tulane University School of Medicine
New Orleans, Louisiana, 70112
Veterans Affairs Medical Center - New York
New York, New York, 10010
NYU School of Medicine's Kaplan Comprehensive Cancer Center
New York, New York, 10016
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021
New York Presbyterian Hospital - Cornell Campus
New York, New York, 10021
Mount Sinai Medical Center, NY
New York, New York, 10029
Herbert Irving Comprehensive Cancer Center
New York, New York, 10032
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
BroMenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center
Normal, Illinois, 61761
William W. Backus Hospital
Norwich, Connecticut, 06360
Hematology Oncology Associates of Illinois, LLC
Oak Park, Illinois, 60304
CCOP - Bay Area Tumor Institute
Oakland, California, 94609-3305
Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin, 53066
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma, 73104
Veterans Affairs Medical Center - Oklahoma City
Oklahoma City, Oklahoma, 73104
Veterans Affairs Medical Center - Omaha
Omaha, Nebraska, 68105
Oncology Hematology West, P.C.
Omaha, Nebraska, 68114
Alegent Health - Immanuel Medical Center
Omaha, Nebraska, 68122
Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Creighton University Cancer Center
Omaha, Nebraska, 68131-2197
St. Joseph Hospital
Omaha, Nebraska, 68131-2197
University of Nebraska Medical Center
Omaha, Nebraska, 68198-3330
Burgess Health Center
Onawa, Iowa, 51040
Chao Family Comprehensive Cancer Center
Orange, California, 92868
St. Charles Hospital
Oregon, Ohio, 43616
Community Hospital of Ottawa
Ottawa, Illinois, 61350
Oncology & Hematology of Ottumwa, PC
Ottumwa, Iowa, 52501
Ottumwa Regional Health Center
Ottumwa, Iowa, 52501
Veterans Affairs Medical Center - Palo Alto
Palo Alto, California, 94304
Alegent Health-Midlands Community Hospital
Papillion, Nebraska, 68046-4194
Pekin Hospital
Pekin, Illinois, 61554
Illinois Oncology Research Association
Peoria, Illinois, 61602
Oncology/Hematology Associates of Central Illinois, P.C.
Peoria, Illinois, 61602
Affiliated Urology Specialists
Peoria, Illinois, 61603
Midwest Urological Group
Peoria, Illinois, 61603
Peoria Urological Associates
Peoria, Illinois, 61614
Proctor Hospital
Peoria, Illinois, 61614
Methodist Medical Center of Illinois
Peoria, Illinois, 61636
Midwest Radiation Oncology Physicians
Peoria, Illinois, 61636
St. Francis Medical Center
Peoria, Illinois, 61637
Illinois Valley Community Hospital
Peru, Illinois, 61354
Canada31 sites
William Osler Health Centre
Brampton, Ontario, L6W 2Z8
Queen Elizabeth Hospital, PEI
Charlottetown, Prince Edward Island, C1A 8T5
Cross Cancer Institute
Edmonton, Alberta, T6G 1Z2
Northeastern Ontario Regional Cancer Centre, Sudbury
Greater Sudbury, Ontario, P3E 5J1
Hopital Charles Lemoyne
Greenfield Park, Quebec, J4V 2H1
Nova Scotia Cancer Centre
Halifax, Nova Scotia, B3H 1V7
British Columbia Cancer Agency - Centre for the Southern Interior
Kelowna, British Columbia, V1Y 5L3
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, N6A 4L6
Trillium Health Centre
Mississauga, Ontario, L5B 1B8
Credit Valley Hospital
Mississauga, Ontario, L5M 2N1
Maisonneuve-Rosemont Hospital
Montreal, Quebec, H1T 2M4
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, H2L-4M1
CHUM Hopital Saint-Luc
Montreal, Quebec, H2X 3J4
Nanaimo Cancer Clinic
Nanaimo, British Columbia, V9S 2B7
Southlake Regional Health Centre
Newmarket, Ontario, L3Y 2P9
Lions Gate Hospital
North Vancouver, V7L 2P9
Peterborough Oncology Clinic
Peterborough, Ontario, K9H 7B6
Allan Blair Cancer Centre
Regina, Saskatchewan, S4T 7T1
Pasqua Hospital
Regina, Saskatchewan, S4T 7T1
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, S7N 4H4
Algoma District Medical Group
Sault Ste. Marie, Ontario, P6B 1Y5
Hotel Dieu Health Sciences Hospital - Niagara
St. Catharines, Ontario, L2R 5K3
L'Hopital Laval
Ste-Foy, Quebec, G1V 4G5
British Columbia Cancer Agency - Fraser Valley Cancer Centre
Surrey, British Columbia, V3V 1Z2
Northwestern Ontario Regional Cancer Centre, Thunder Bay
Thunder Bay, Ontario, P7A 7T1
Mount Sinai Hospital - Toronto
Toronto, Ontario, M5G 1X5
Saint Joseph's Health Centre - Toronto
Toronto, Ontario, M6R 1B5
British Columbia Cancer Agency
Vancouver, British Columbia, V5Z 4E6
British Columbia Cancer Agency - Vancouver Island Cancer Centre
Victoria, British Columbia, V8R 6V5
Humber River Regional Hospital
Weston, Ontario, M9N 1N8
St. Boniface General Hospital
Winnipeg, Manitoba, R2H 2A6
Puerto Rico3 sites
Centro Mamografia Hospital Oncologico
Hato Rey, 00919-1811
Veterans Affairs Medical Center - San Juan
San Juan, 00927-5800
San Juan City Hospital
San Juan, 00936-7344
South Africa2 sites
Medical Oncology Centre of Rosebank
Johannesburg, 2193
Pretoria Academic Hospitals
Pretoria, 0001
About this study
Official title: A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is most effective in treating advanced colorectal cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have advanced, recurrent, or metastatic colorectal cancer that cannot be treated with surgery or radiation therapy.
Read the detailed description
OBJECTIVES:
- Compare the time to progression in patients with locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma treated with combinations of oxaliplatin, fluorouracil, leucovorin calcium, and irinotecan.
- Compare the quality of life, response rate, time to treatment failure, and overall survival in patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to ECOG performance status (0-1 vs 2), prior adjuvant chemotherapy (yes vs no), prior immunotherapy (yes vs no), and age (under 65 vs 65 and over). Patients are randomized to one of three treatment arms.
Only arm II remains open to accrual.
- Arm I (Saltz regimen): Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks. (Arm I closed to accrual as of March 15, 2002.)
- Arm II (FOLFOX4 regimen): Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks.
- Arm III (oxaliplatin plus irinotecan): Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks. (Arm III closed to accrual as of March 15, 2002.) Treatment continues in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.
Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 825 patients (275 per arm) have been accrued for this study thus far. Additional patients are being accrued on arm II. (Arms I and III closed to accrual as of March 15, 2002.)
- Conditions
- Colorectal Cancer
- Being tested
- irinotecan, fluorouracil, leucovorin calcium, oxaliplatin
- Keywords
- stage III colon cancer, stage IV colon cancer, stage III rectal cancer, stage IV rectal cancer, recurrent colon cancer, recurrent rectal cancer, adenocarcinoma of the colon, adenocarcinoma of the rectum
- Medical subject headings
- Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
irinotecanDrug
fluorouracilDrug
oxaliplatinDrug
| Study group | Role | What they receive |
|---|---|---|
| irinotecan + leucovorin + fluorouracil | Experimental | Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.
Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. Receives: Drug: irinotecan; Drug: fluorouracil; Drug: leucovorin calcium |
| oxaliplatin + leucovorin + fluorouracil | Experimental | Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.
Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. Receives: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin |
| oxaliplatin + irinotecan | Experimental | Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks.
Treatment continues in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.
Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. Receives: Drug: irinotecan; Drug: oxaliplatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
time to progression
Measured: Up to 5 years
Secondary outcomes (4)
overall survival
Measured: Up to 5 years
time to treatment failure
Measured: Up to 5 years
response rate
Measured: Up to 5 years
quality of life
Measured: Up to 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2003 (estimated)
- Study startOct 1998
- Primary completionOct 2004
- Study completionOct 2004
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (28)Papers the sponsor has linked to this study.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- More trials run by Alliance for Clinical Trials in OncologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,691 participants (actual)
Sponsor and investigators
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Sponsor type
- University, hospital or other
- Collaborators
- National Cancer Institute (NCI), NCIC Clinical Trials Group
- Responsible party
- Sponsor
- Investigators
- Henry C. Pitot, MD, Study chair, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00003594
- Sponsor's protocol ID
- NCCTG-N9741
- Other IDs
- CDR0000066665, CAN-NCIC-CO13
- Status last verified
- Apr 2020
- First submitted
- 1 Nov 1999
- Last updated
- 29 Apr 2020
- Results posted
- No
- Data monitoring committee
- No
Publications
Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12.
PubMed 22162570An MW, Mandrekar SJ, Branda ME, Hillman SL, Adjei AA, Pitot HC, Goldberg RM, Sargent DJ. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clin Cancer Res. 2011 Oct 15;17(20):6592-9. doi: 10.1158/1078-0432.CCR-11-0822. Epub 2011 Aug 31.
PubMed 21880789Campbell ME, Mandrekar SJ, Hillman SL, et al.: What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings. [Abstract] J Clin Oncol 26 (Suppl 15): A-6520, 2008.
Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008 Jan 10;26(2):183-9. doi: 10.1200/JCO.2007.13.8099.
PubMed 18182660Grothey A, Hedrick EE, Mass RD, et al.: Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC): a comparative analysis of N9741 and AVF2107. [Abstract] J Clin Oncol 24 (Suppl 18): A-3516, 2006.
Goldberg R. Oxaliplatin in colorectal cancer: current studies. Oncology (Williston Park). 2000 Dec;14(12 Suppl 11):42-7.
PubMed 11204663Heun JM, Grothey A, Branda ME, Goldberg RM, Sargent DJ. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. Oncologist. 2011;16(6):859-67. doi: 10.1634/theoncologist.2011-0064. Epub 2011 May 31.
PubMed 21632455Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol. 2011 Apr 20;29(12):1599-606. doi: 10.1200/JCO.2010.31.7255. Epub 2011 Mar 21.
PubMed 21422438Goldberg RM, Sargent DJ, McLeod H. Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Trans Am Clin Climatol Assoc. 2010;121:21-32; discussion 32-3.
PubMed 20697547McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010 Jul 10;28(20):3227-33. doi: 10.1200/JCO.2009.21.7943. Epub 2010 Jun 7.
PubMed 20530282Goldberg RM, Sargent DJ, Morton RF, Green E, Sanoff HK, McLeod H, Buckner J. NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. Oncologist. 2009 Oct;14(10):970-8. doi: 10.1634/theoncologist.2009-0175. Epub 2009 Oct 14.
PubMed 19828593Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009 Sep 1;27(25):4109-15. doi: 10.1200/JCO.2009.21.9527. Epub 2009 Jul 27.
PubMed 19636001Fuchs CS, Goldberg RM, Sargent DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res. 2008 Dec 15;14(24):8263-9. doi: 10.1158/1078-0432.CCR-08-0480. Epub 2008 Dec 10.
PubMed 19073970Sanoff HK, Sargent DJ, Campbell ME, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Goldberg RM. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008 Dec 10;26(35):5721-7. doi: 10.1200/JCO.2008.17.7147. Epub 2008 Nov 10.
PubMed 19001325Sargent DJ, Campbell M, Grothey A, et al.: Overall and 12 week tumor response versus actual tumor measurements as predictors of overall survival (OS) in advanced colorectal cancer (ACRC): findings from NCCTG N9741. [Abstract] American Society of Clinical Oncology 2008 Gastrointestinal Cancers Symposium, 25-27 January 2008, Orlando, FL. A-446, 2008.
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum
- ClinicalTrials.gov ID
- NCT00003594
- Acronym / sponsor ID
- NCCTG-N9741
- Conditions
- Colorectal Cancer
- Keywords
- stage III colon cancer, stage IV colon cancer, stage III rectal cancer, stage IV rectal cancer, recurrent colon cancer, recurrent rectal cancer, adenocarcinoma of the colon, adenocarcinoma of the rectum
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,691 participants (actual)
- Lead sponsor
- Alliance for Clinical Trials in OncologyUniversity, hospital or other
- Collaborators
- National Cancer Institute (NCI), NCIC Clinical Trials Group
- Study start
- Oct 1998
- Primary completion
- Oct 2004 (actual)
- Study completion
- Oct 2004 (actual)
- First posted
- 25 Sep 2003 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is most effective in treating advanced colorectal cancer.
PURPOSE: Randomized phase III trial to compare the effectiveness of various combination chemotherapy regimens in treating patients who have advanced, recurrent, or metastatic colorectal cancer that cannot be treated with surgery or radiation therapy.
Detailed description
OBJECTIVES:
- Compare the time to progression in patients with locally advanced, locally recurrent, or metastatic colorectal adenocarcinoma treated with combinations of oxaliplatin, fluorouracil, leucovorin calcium, and irinotecan.
- Compare the quality of life, response rate, time to treatment failure, and overall survival in patients treated with these regimens.
- Compare the toxicity of these regimens in these patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to ECOG performance status (0-1 vs 2), prior adjuvant chemotherapy (yes vs no), prior immunotherapy (yes vs no), and age (under 65 vs 65 and over). Patients are randomized to one of three treatment arms.
Only arm II remains open to accrual.
- Arm I (Saltz regimen): Patients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks. (Arm I closed to accrual as of March 15, 2002.)
- Arm II (FOLFOX4 regimen): Patients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks.
- Arm III (oxaliplatin plus irinotecan): Patients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks. (Arm III closed to accrual as of March 15, 2002.) Treatment continues in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment.
Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter.
PROJECTED ACCRUAL: A total of 825 patients (275 per arm) have been accrued for this study thus far. Additional patients are being accrued on arm II. (Arms I and III closed to accrual as of March 15, 2002.)
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| irinotecan + leucovorin + fluorouracil | Experimental | Drug: irinotecan, Drug: fluorouracil, Drug: leucovorin calciumPatients receive irinotecan IV over 90 minutes followed by leucovorin calcium IV over 15 minutes and fluorouracil IV once a week for 4 weeks followed by 2 weeks of rest. Courses repeat every 6 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. |
| oxaliplatin + leucovorin + fluorouracil | Experimental | Drug: fluorouracil, Drug: leucovorin calcium, Drug: oxaliplatinPatients receive oxaliplatin IV over 2 hours on day 1 and leucovorin calcium IV over 2 hours plus fluorouracil IV over 22 hours on days 1 and 2. Courses repeat every 2 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. |
| oxaliplatin + irinotecan | Experimental | Drug: irinotecan, Drug: oxaliplatinPatients receive oxaliplatin IV over 2 hours and irinotecan IV over 30 minutes on day 1. Courses repeat every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed before treatment, during treatment (arm specific), and after completion of treatment. Patients are followed every 3 months for 1 year, every 6 months for 2 years, and then annually thereafter. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| irinotecan | Drug | irinotecan + leucovorin + fluorouracil, oxaliplatin + irinotecan |
| fluorouracil | Drug | irinotecan + leucovorin + fluorouracil, oxaliplatin + leucovorin + fluorouracil |
| leucovorin calcium | Drug | irinotecan + leucovorin + fluorouracil, oxaliplatin + leucovorin + fluorouracil |
| oxaliplatin | Drug | oxaliplatin + irinotecan, oxaliplatin + leucovorin + fluorouracil |
Primary outcome
time to progression
Time frame: Up to 5 years
4 secondary outcomes
overall survival
Time frame: Up to 5 years
time to treatment failure
Time frame: Up to 5 years
response rate
Time frame: Up to 5 years
quality of life
Time frame: Up to 5 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2020.
- Background: PubMed 22162570Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012 Jan 20;30(3):263-7. doi: 10.1200/JCO.2011.37.1039. Epub 2011 Dec 12.
- Background: PubMed 21880789An MW, Mandrekar SJ, Branda ME, Hillman SL, Adjei AA, Pitot HC, Goldberg RM, Sargent DJ. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clin Cancer Res. 2011 Oct 15;17(20):6592-9. doi: 10.1158/1078-0432.CCR-11-0822. Epub 2011 Aug 31.
- BackgroundCampbell ME, Mandrekar SJ, Hillman SL, et al.: What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings. [Abstract] J Clin Oncol 26 (Suppl 15): A-6520, 2008.
- Background: PubMed 18182660Grothey A, Hedrick EE, Mass RD, Sarkar S, Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM, Sargent DJ. Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. J Clin Oncol. 2008 Jan 10;26(2):183-9. doi: 10.1200/JCO.2007.13.8099.
- BackgroundGrothey A, Hedrick EE, Mass RD, et al.: Response rate using conventional criteria is a poor surrogate for clinical benefit on progression-free (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC): a comparative analysis of N9741 and AVF2107. [Abstract] J Clin Oncol 24 (Suppl 18): A-3516, 2006.
- Background: PubMed 11204663Goldberg R. Oxaliplatin in colorectal cancer: current studies. Oncology (Williston Park). 2000 Dec;14(12 Suppl 11):42-7.
- Results publication: PubMed 21632455Heun JM, Grothey A, Branda ME, Goldberg RM, Sargent DJ. Tumor status at 12 weeks predicts survival in advanced colorectal cancer: findings from NCCTG N9741. Oncologist. 2011;16(6):859-67. doi: 10.1634/theoncologist.2011-0064. Epub 2011 May 31.
- Results publication: PubMed 21422438Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS. Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. J Clin Oncol. 2011 Apr 20;29(12):1599-606. doi: 10.1200/JCO.2010.31.7255. Epub 2011 Mar 21.
- Results publication: PubMed 20697547Goldberg RM, Sargent DJ, McLeod H. Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics. Trans Am Clin Climatol Assoc. 2010;121:21-32; discussion 32-3.
- Results publication: PubMed 20530282McLeod HL, Sargent DJ, Marsh S, Green EM, King CR, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Thibodeau SN, Grothey A, Morton RF, Goldberg RM. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol. 2010 Jul 10;28(20):3227-33. doi: 10.1200/JCO.2009.21.7943. Epub 2010 Jun 7.
- Results publication: PubMed 19828593Goldberg RM, Sargent DJ, Morton RF, Green E, Sanoff HK, McLeod H, Buckner J. NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial. Oncologist. 2009 Oct;14(10):970-8. doi: 10.1634/theoncologist.2009-0175. Epub 2009 Oct 14.
- Results publication: PubMed 19636001Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol. 2009 Sep 1;27(25):4109-15. doi: 10.1200/JCO.2009.21.9527. Epub 2009 Jul 27.
- Data Available: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data ArchiveLink provided by the sponsor.
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Henry C. Pitot, MD study chair
Mayo Clinic
466 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing irinotecan, fluorouracil and leucovorin calcium in people with Colorectal Cancer, run by Alliance for Clinical Trials in Oncology at 466 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Apr 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 466 sites in United States, Canada, Puerto Rico, South Africa. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
time to progression (time frame: Up to 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00003594, which also lists 28 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2020.